Vitrolife

Vitrolife EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vitrolife (VITR.ST) as of Nov 10, 2026 is 869.00 M SEK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 1.05 B SEK — a change of -17.00% (lower).

EBITDA

869.00 MSEK

YoY

-17.00%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vitrolife is 2025 869.00 M SEK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vitrolife was 2024 1.05 B SEK. It decreases by -17.00% lower compared to the previous year.

The Vitrolife EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
399.07 M SEK
Jan 1, 2019
509.88 M SEK
Jan 1, 2020
391.35 M SEK
Jan 1, 2021
482.91 M SEK
Jan 1, 2022
880.00 M SEK
Jan 1, 2023
-3.36 B SEK
Jan 1, 2024
1.05 B SEK
Jan 1, 2025
869.00 M SEK
The Vitrolife EBITDA history
YEAREBITDAYoY
869.00 MSEK-17.00%
1.05 BSEK-131.15%
-3.36 BSEK-481.93%
880.00 MSEK+82.23%
482.91 MSEK+23.40%
391.35 MSEK-23.25%
509.88 MSEK+27.77%
399.07 MSEK+14.94%
347.18 MSEK+35.16%
256.88 MSEK+13.59%
226.14 MSEK+57.75%
143.35 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vitrolife Stock analysis

What does Vitrolife do? Vitrolife AB is a Swedish biotech company specializing in the development and marketing of products for in vitro fertilization (IVF) and regenerative medicine. It was founded in 1994 and has over 390 employees worldwide. The company's main business is IVF, offering a wide range of essential products for IVF treatment such as culture media, devices for semen analysis and preparation, embryo transfer techniques, and products for biopsy examinations and cryopreservation. Vitrolife has a presence in 110 countries and has expanded its market to China where there is a high demand for fertility treatments. The company also offers medical equipment for regenerative treatments. Vitrolife is a leading player in the IVF industry known for its high product quality and innovation. It collaborates with universities and research institutions globally to improve IVF technology and success rates. The company places importance on sustainability and environmental protection, using 100% animal-free ingredients in their culture media and practicing recycling and waste reduction in their production facilities. In summary, Vitrolife offers a wide range of products for IVF and regenerative medicine, with a focus on supporting IVF treatments. The company is a leader in its industry and actively participates in research. It is committed to sustainability and environmental responsibility. Vitrolife is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vitrolife stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vitrolife is 869.00 M SEK in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vitrolife changed from 1.05 B SEK to 869.00 M SEK, representing a -17.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Vitrolife since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Vitrolife historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Vitrolife

All Key Metrics — Vitrolife